Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREV: Prednisone plus everolimus in metastatic renal cell carcinoma after VEGFR TKI failure
2015-002419-14Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prednisone and everolimus in metastatic renal cell carcinoma (mRCC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Incidence of grade ≥ 2 stomatitis and Incidence of non-infectious pneumonitis. Started Sep 2018; status: terminated.
02
Drugs
prednisoneeverolimus
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2015-002419-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002419-14.